Christian P. Strassburg

Christian P. Strassburg

Auto-generated profile, based on publicly available information

Christian P. Strassburg

Department of General Internal Medicine I, University of Bonn, 53127 Bonn, Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in The Journal of Pediatrics
Verified
Journal Article
Closed access
MWMarek Woynarowski
Marek Woynarowski
ANAntal Nemeth
Antal Nemeth
YBYaacov Baruch
Yaacov Baruch
SKSibylle Koletzko
Sibylle Koletzko
MMMichael Melter
Michael Melter
MMMichael Manns
Michael Manns

13 January 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MGMaria Gonzalez-Carmona
Maria Gonzalez-Carmona
MBMaximilian Bolch
Maximilian Bolch
CJChristian Jansen
Christian Jansen
AVAnnabelle Vogt
Annabelle Vogt
MSMatthias Sampels
Matthias Sampels
TWTobias J. Weismüller
Tobias J. Weismüller
Summary: Background: Chemotherapy with gemcitabine and cisplatin is the current standard for patients with unresectable cholangiocarcinoma. Local photodynamic therapy has also demonstrated benefit in patients with extrahepatic cholangiocarcinoma.Aim: To evaluate the benefit of photodynamic therapy in combination with systemic chemotherapy in advanced extrahepatic cholangiocarcinoma.Methods: Three hundred and fifty‐three patients diagnosed with cholangiocarcinoma between 2004 and 2016 were treated at the University Hospital of Bonn, Germany. Of these, 96 suffering from unresectable extrahepatic cholangiocarcinoma were included. Patients were stratified according to treatment: combination photodynamic therapy and chemotherapy (36 patients), photodynamic therapy alone (34 patients), and chemotherapy alone (26 patients).Results: Combined photodynamic therapy with chemotherapy resulted in significantly longer overall survival than chemotherapy alone (P = 0.022). Median survival was 20 months in the combination group (95% CI: 16.38‐23.62), 15 months in the photodynamic alone group (95% CI: 10.02‐19.98) and 10 months in the chemotherapy alone group (95% CI: 8.45‐11.55). In multivariate analysis, combination therapy and photodynamic therapy alone (HR: 0.41, 95% CI: 0.22‐0.77, P = 0.006), metal stenting, and radiofrequency ablation were independent predictors of longer survival.Conclusions: Combination photodynamic therapy and chemotherapy was well tolerated and resulted in significantly longer survival than chemotherapy alone. Application of photodynamic therapy significantly correlated with longer survival, demonstrating benefit in advanced cholangiocarcinoma. Thus, photodynamic therapy should be considered during therapeutic decision making in advanced cholangiocarcinoma.

3 July 2019 in Gut
Verified
Journal Article
Open access
PDF file
AQAlexander Queck
Alexander Queck
RCRoberto Carnevale
Roberto Carnevale
FUFrank Erhard Uschner
Frank Erhard Uschner
RSRobert Schierwagen
Robert Schierwagen
SKSabine Klein
Sabine Klein
JTJonel Trebicka
Jonel Trebicka

7 June 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MRMartin Rössle
Martin Rössle
DBDominik Bettinger
Dominik Bettinger
JTJonel Trebicka
Jonel Trebicka
CKChristoph Klinger
Christoph Klinger
MPMichael Praktiknjo
Michael Praktiknjo
MSMichael Schultheiß
Michael Schultheiß
Summary: Background: To evaluate medical versus interventional treatment (transjugular thrombus fragmentation, local thrombolysis with or without stent implantation) in patients with acute non‐cirrhotic, non‐malignant portal vein thrombosis (PVT).Methods: This prospective, observational study enrolled 65 patients with acute (<28 days since begin of symptoms, no cavernoma) PVT in nine centres. Thirty patients received medical treatment and 35 patients received interventional treatment. PVT was graded into grade 1: short thrombosis and incomplete occlusion of the vessel lumen and grade 2: extended thrombosis or complete occlusion. Treatment response was classified as partial or complete, if thrombosis was reduced by one grade or to <25% of the vessel diameter respectively.Results: Partial and complete response rates were 7% and 30% in the medical compared to 17% and 54% (P < 0.001) in the interventional treatment group. In the multivariate analysis, interventional treatment showed a strong positive (OR 4.32, P < 0.016) and a myeloproliferative aetiology a negative (OR 0.09, P = 0.006) prediction of complete response. Complications were rare in the medical group and consisted of septicaemia and upper gastrointestinal bleeding of unknown origin in one patient each. Interventional treatment was accompanied by mild and self‐limiting bleeding complications in nine patients, moderate intra‐abdominal bleeding requiring transfusions (2 units) in one patient and peritoneal bleeding requiring surgical rescue in one patient. Four patients in each group developed intestinal gangrene requiring surgery. One patient died 52 days after unsuccessful interventional treatment.Conclusions: Compared to medical treatment alone, interventional treatment doubled response rates at the cost of increased bleeding complications.

4 July 2022 in Gut
Verified
Journal Article
Open access
PDF file
SBStephan Buch
Stephan Buch
HIHamish Innes
Hamish Innes
PLPhilipp Ludwig Lutz
Philipp Ludwig Lutz
HNHans Dieter Nischalke
Hans Dieter Nischalke
JMJens U Marquardt
Jens U Marquardt
FSFelix Stickel
Felix Stickel
Objective: Hepatocellular carcinoma (HCC) often develops in patients with alcohol-related cirrhosis at an annual risk of up to 2.5%. Some host genetic risk factors have been identified but do not account for the majority of the variance in occurrence. This study aimed to identify novel susceptibility loci for the development of HCC in people with alcohol related cirrhosis. Design: Patients with alcohol-related cirrhosis and HCC (cases: n=1214) and controls without HCC (n=1866), recruited from Germany, Austria, Switzerland, Italy and the UK, were included in a two-stage genome-wide association study using a case–control design. A validation cohort of 1520 people misusing alcohol but with no evidence of liver disease was included to control for possible association effects with alcohol misuse. Genotyping was performed using the InfiniumGlobal Screening Array (V.24v2, Illumina) and the OmniExpress Array (V.24v1-0a, Illumina). Results: Associations with variants rs738409 in PNPLA3 and rs58542926 in TM6SF2 previously associated with an increased risk of HCC in patients with alcohol-related cirrhosis were confirmed at genome-wide significance. A novel locus rs2242652(A) in TERT (telomerase reverse transcriptase) was also associated with a decreased risk of HCC, in the combined meta-analysis, at genome-wide significance (p=6.41×10−9, OR=0.61 (95% CI 0.52 to 0.70). This protective association remained significant after correction for sex, age, body mass index and type 2 diabetes (p=7.94×10−5, OR=0.63 (95% CI 0.50 to 0.79). Carriage of rs2242652(A) in TERT was associated with an increased leucocyte telomere length (p=2.12×10−44). Conclusion: This study identifies rs2242652 in TERT as a novel protective factor for HCC in patients with alcohol-related cirrhosis.

Verified
Journal Article
Open access
PDF file
TMTudor Voicu Mocan
Tudor Voicu Mocan
ASAndré Simão
André Simão
RCRui Castro
Rui Castro
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
Artur SłomkaArtur Słomka
Artur Słomka
Miroslaw KornekMiroslaw Kornek
Miroslaw Kornek
Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide and the third most common cause of cancer-related death. One of the major problems faced by researchers and clinicians in this area is the lack of reliable disease biomarkers, which would allow for an earlier diagnosis, follow-up or prediction of treatment response, among others. In this regard, the “HCC circulome”, defined as the pool of circulating molecules in the bloodstream derived from the primary tumor, represents an appealing target, the so called liquid biopsy. Such molecules encompass circulating tumor proteins, circulating tumor cells (CTCs), extracellular vesicles (EVs), tumor-educated platelets (TEPs), and circulating tumor nucleic acids, namely circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA). In this article, we summarize recent findings highlighting the promising role of liquid biopsies as novel potential biomarkers in HCC, emphasizing on its clinical performance.